MRNA
Moderna IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$18.22B
P/E Ratio
—
EPS
$-7.26
Beta
1.34
52W High
$59.55
52W Low
$22.28
50-Day MA
$51.85
200-Day MA
$35.64
Dividend Yield
—
Profit Margin
-145.20%
Forward P/E
23.04
PEG Ratio
0.00
About Moderna Inc
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $1.94B |
| Gross Profit (TTM) | $-2.06B |
| EBITDA | $-2.86B |
| Operating Margin | -126.40% |
| Return on Equity | -28.90% |
| Return on Assets | -14.50% |
| Revenue/Share (TTM) | $5.00 |
| Book Value | $21.95 |
| Price-to-Book | 2.10 |
| Price-to-Sales (TTM) | 9.37 |
| EV/Revenue | 7.1 |
| EV/EBITDA | 4.64 |
| Quarterly Earnings Growth (YoY) | -85.10% |
| Quarterly Revenue Growth (YoY) | -29.80% |
| Shares Outstanding | $396.59M |
| Float | $368.43M |
| % Insiders | 7.32% |
| % Institutions | 76.94% |
Historical Volatility
HV 10-Day
41.46%
HV 20-Day
43.47%
HV 30-Day
47.43%
HV 60-Day
59.55%
HV Rank
5.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($41.42 target)
2
Strong Buy2
Buy17
Hold1
Sell2
Strong SellData last updated: 5/1/2026